CAS: 327-97-9; (1S,3R,4R,5R)-3-(((3-(3,4-Dihydroxyphenyl)Acryloyl)Oxy)-1,4,5-Trihydroxycyclohexanecarboxylic Acid

上下游产品

CAS号82592-68-5 [2-acetyloxy-4-... | CAS号202650-88-2 (-)-5-Caffeoyl ... | CAS号176798-26-8 (2S,3S,4aR,6S,8... | CAS号32719-11-2 3-mono-O-caffeo... | CAS号32719-11-2 3-mono-O-caffeo... | CAS号331-39-5 咖啡酸 | CAS号77-95-2 D-(-)-奎宁酸 | CAS号905-99-7 隐绿原酸 | CAS号202650-88-2 (-)-5-Caffeoyl ... | CAS号14534-61-3 异绿原酸B | CAS号99-50-3 原儿茶酸 | CAS号3843-74-1 咖啡酸甲酯

Neochlorogenic Acid 以 水 作为反应溶剂,化学反应 0.5H,反应生成 绿原酸,4-O-Caffeoylquinic Acid
参考文献:Polyphenols Are Intensively Metabolized In The Human Gastrointestinal Tract After Apple Juice Consumption
标题:Polyphenols Are Intensively Metabolized In The Human Gastrointestinal Tract After Apple Juice Consumption
摘要:Polyphenols Are Secondary Plant Compounds Showing Anticarcinogenic Effects Both In Vitro And In Animal Experiments And May Thus Reduce The Risk Of Colorectal Cancer In Man. The Identification Of Polyphenol Metabolites Formed Via Their Passage Through The Small Intestine Of Healthy Ileostomy Subjects After Apple Juice Consumption Is Presented. Identification And Quantification Of Polyphenols And Their Metabolites Were Performed Using HPLC-Dad As Well As HPLC-Esi-Ms/ms. Total Procyanidin Content (Tpa) Was Measured,And Additionally The Mean Degree Of Polymerization (Dpm) Of The Procyanidins Was Determined In The Apple Juice And Ileostomy Effluents. As Products Of Polyphenol Metabolism,D-(-)-Quinic Acid And Methyl Esters Of Caffeic Acid And P-Coumaric Acid Are Liberated From The Corresponding Hydroxycinnamic Acid Esters. 1-Caffeoylquinic Acid And 3-Caffeoylquinic Acid Were Determined As Products Of Isomerization. Phloretin 2'-O-Glucoside (Phloridzin) And Phloretin 2'-O-Xyloglucoside Were Metabolized Into The Corresponding Aglycons Phloretin And Phloretin 2'-O-Glucuronide And All Were Found In The Ileostomy Effluent. Ninety Percent Of The Consumed Procyanidins Were Recovered In The Ileostomy Effluent And Therefore Would Reach The Colon Under Physiologic Circumstances. The Dpm Was Reduced (Dpm Of Apple Juice = 5.7) And Varied Depending On The Time Point Of Excretion. The Gastrointestinal Passage Seems To Play An Important Role In The Colonic Availability Of Apple Polyphenols.
DOI:10.1021/jf071942R

专利信息

专利号:US-2008233242-A1
优先权日:2003-10-08
标 题:Antioxidant of Bamboo Leaves and Its Uses
发明人：ZHANG YING; WU XIAOQIN; YU ZHUOYU; LUO DINGDING; LU BOYI; ZHANG YU
权利人:ZHANG YING; WU XIAOQIN; YU ZHUOYU; LUO DINGDING; LU BOYI; ZHANG YU
摘要:The present invention discloses the composition of antioxidant of bamboo leaves (AOB) and its use. The purpose of present invention is to provide a new food additive which is natural, nutritional, and muti-functional, and which is of rich resources, safety, good effect, and low cost. AOB is yellow or brown powders or particles obtained from bamboo leaves, wherein the main antioxidative components include flavones, lactones, phenolic acids. AOB can either inhibit lipid autoxidation chain reaction, or chelate transitional metal ions, and can be used as primary and second antioxidant. AOB can eliminate nitrite and inhibit the synthesis of N-nitrosamine, and has anti-bacteria, bacteriostatic, deodorizing, aroma enhancing etc. functions. AOB can be commonly used in oil-containing food, meat product, fishery product, expanded food etc. food systems.

专利号:US-2004110228-A1
优先权日:2002-04-01
标 题:Combinatorial organic synthesis of unique biologically active compounds
发明人：MCALPINE SHELLI R; TAYLOR RACHEL E; BOLLA MEGAN L; SEGALL ANCA M
摘要:The invention provides a method for making a combinatorial library of cyclic compounds, such as Holliday junction-trapping compounds, comprising the steps of (a) obtaining a plurality of trimers according to the generic structure X 1- X 2- X 3 , wherein X 1 , X 2 and X 3 can be independently any naturally or nonnaturally occurring amino acids or peptidomimetics thereof; (b) optionally coupling a spacer S to the trimer at either end; (c) cyclizing two trimers or trimer-spacer conjugates in a head-to-tail orientation; thereby obtaining a combinatorial library of compounds, wherein the library does not include an unmodifed or naturally occurring Holliday Junction-trapping compounds. The invention additionally provides methods macrocyclic compounds that are synergimycin derivatives.

专利号:US-7825268-B2
优先权日:2003-12-23
标 题:Alkoxylactones, alkoxylactams and alkoxythiolactams for controlling processes based on microbial interaction
发明人：STUMPE STEFAN; BREVES ROLAND; HUCHEL URSULA; JANSSEN FRANK; HAETZELT ANDRE
权利人:HENKEL AG & CO KGAA
摘要:Compounds of the Formula I, n nwherein A 1 is O or NH; A 2 is O or S; each of R 1 and R 2 is independently hydrogen, a methyl or C 2 -C 8 -saturated or mono- or doubly unsaturated, branched or linear hydrocarbon group; and R 3 is a C 1 -C 18 -saturated or mono- or doubly unsaturated, branched or linear hydrocarbon group wherein, each of R 1 , R 2 and R 3 comprises a heteroatom selected from the group consisting of O and S in the chain and/or is mono- or multiply-substituted by a substituent selected from the group consisting of halogen, hydroxy, C 1 -C 6 -alkyl, trifluoromethyl, C 1 -C 6 -alkoxy, C 6 -C 10 -aryl, and C 1 -C 6 -alkyl-C 6 -C 10 -aryl are useful for controlling the interaction process between microorganisms such as in the development and/or maturation of biofilms; multicellular swarm behavior; the concerted development of antibiotic resistances; the concerted synthesis of antibiotics; the concerted synthesis of pigments; the concerted production of extracellular enzymes; or the concerted production of virulence factors.

专利号:US-2004086526-A1
优先权日:2002-07-17
标 题 :Process for protecting the skin against aging
发明人：DANOUX LOUIS; FREIS OLGA; PAULY GILLES
摘要:The invention relates to a process for the production of preparations for stimulating human skin cells and for protection against aging of the skin and the harmful effects of environmental toxins and UV radiation, characterized in that the preparations contain at least one substance which increases the synthesis of energy donors of the mitochondrial respiratory chain and, at the same time, lowers the level of reactive oxygen species (ROS) in the cell metabolism. The invention also relates to the use of cosmetic and/or pharmaceutical preparations containing at least one substance which increases the synthesis of energy donors of the mitochondrial respiratory chain and, at the same time, lowers the level of reactive oxygen species (ROS) in the cell metabolism for stimulating human skin cells and for protection against aging of the skin and against the harmful effects of environmental toxins and UV radiation.

专利号:US-2006078533-A1
优先权日:2004-10-12
标 题:Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
发明人：OMOIGUI OSEMWOTA S
权利人:OMOIGUI OSEMWOTA S
摘要:This invention relates to a method for prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and/or inhibition of the signal transduction pathway.

专利号:US-2006275294-A1
优先权日:2002-08-22
标题:Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
发明人：OMOIGUI OSEMWOTA S
权利人:OMOIGUI OSEMWOTA S
摘要:This invention relates to a method for prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging, age-related disorders and/or age-related manifestations including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and/or inhibition of the signal transduction pathway